These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17073636)

  • 1. The pathophysiology of oxaliplatin-induced neurotoxicity.
    Kiernan MC; Krishnan AV
    Curr Med Chem; 2006; 13(24):2901-7. PubMed ID: 17073636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nerve excitability assessment in chemotherapy-induced neurotoxicity.
    Park SB; Lin CS; Kiernan MC
    J Vis Exp; 2012 Apr; (62):. PubMed ID: 22565594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of oxaliplatin-induced neuropathy: a patient perspective.
    Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
    Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
    Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
    McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
    Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin and axonal Na+ channel function in vivo.
    Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
    Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
    Kurniali PC; Luo LG; Weitberg AB
    Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers.
    Zedan AH; Hansen TF; Fex Svenningsen A; Vilholm OJ
    Clin Colorectal Cancer; 2014 Jun; 13(2):73-80. PubMed ID: 24365057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
    Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander M; Kiernan MC
    Curr Med Chem; 2008; 15(29):3081-94. PubMed ID: 19075655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
    Lucchetta M; Lonardi S; Bergamo F; Alberti P; Velasco R; Argyriou AA; Briani C; Bruna J; Cazzaniga M; Cortinovis D; Cavaletti G; Kalofonos HP
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):899-902. PubMed ID: 23108696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
    Padman S; Lee J; Kumar R; Slee M; Hakendorf P; Richards A; Koczwara B; Kichenadasse G; Sukumaran S; Roy A; Vatandoust S; Karapetis CS
    Support Care Cancer; 2015 Mar; 23(3):861-9. PubMed ID: 25223350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
    Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
    Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
    Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axonal excitability changes and acute symptoms of oxaliplatin treatment: In vivo evidence for slowed sodium channel inactivation.
    Heide R; Bostock H; Ventzel L; Grafe P; Bergmans J; Fuglsang-Frederiksen A; Finnerup NB; Tankisi H
    Clin Neurophysiol; 2018 Mar; 129(3):694-706. PubMed ID: 29233604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.